A big announcement for Senseonics (SENS) investors could be waiting on January 1, 2023. The annoucement could be related to BlueCross BlueShield Policy. In August of this year, the company announced Expanded Insurance Coverage for its Eversense system.
Elevance Health’s decision to expand insurance coverage will cover 45 million lives and help them to manage diabetes. The expanded coverage will benefit more than 250 million lives.
Anthem (now Elevance Health) is the second largest health insurance company in the U.S. and a leading health company dedicated to improving lives and communities, and making healthcare simpler. Through its affiliated companies, Anthem serves people across 14 states, including more than 45 million within its family of health plans. This most recent coverage decision, in addition to Cigna, Aetna, Humana, HCSC Blue Cross Blue Shield and other health insurance providers, demonstrates broad-based coverage across the United States from the majority of commercial payers, enabling their members to access the benefits of the long-term Eversense CGM System.
Is Senseonics (SENS) a good stock?
Yes, Senseonics is a good stock to invest in as the diabetes market becomes more than a $26.7 billion dollar industry by 2030, according to an Industry Trend report. The market is primarily driven by factors such as an increase in technological advancements and rise in the incidences of obesity. Moreover, increasing adoption of insulin delivery devices and rising prevalence of diabetes are driving market growth.
